EGFR EDV PLK is under clinical development by ImmunityBio and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EGFR EDV PLK’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EGFR EDV PLK overview
The therapeutic candidate is under development for the treatment of end-stage non-small cell lung cancer and mesothelioma. The therapeutic candidate comprises of cytotoxic drug, siRNA or miRNA packaged into EDV nanocells. It acts by targeting polo like kinase (PLK1). It is developed based on a bacterially-derived EDV nanocell platform.
It was also under development for treatment of multiple cancer indications
ImmunityBio overview
ImmunityBio, a subsidiary of NantWorks LLC, is a clinical-stage biotechnology company developing therapies for therapies for cancer and infectious diseases. The company product pipeline includes anktiva + BCG, anktiva + keytruda (pembrolizumab), aldox + anktiva + PD-L1 t-hank, anktiva + tri-ad5 vaccines, anktiva + bevacizumab + PD-L1 t-hank, anktiva + IBRX-042 vaccination, anktiva + M-ceNK and anktiva + CD19 t-haNK. ImmunityBio pipeline candidates treat bladder cancer, lung cancer, lynch syndrome, pancreatic cancer, glioblastoma, HPV, advanced Solid tumors, non-hodgkin lymphoma and HIV. The company operates in Italy, South Korea and the US. ImmunityBio is headquartered in San Diego, California, the US.
For a complete picture of EGFR EDV PLK’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
